Clinical trial experience with the MitraClip catheter based mitral valve repair system

Francesco Maisano, Cosmo Godino, Andrea Giacomini, Paolo Denti, Iryna Arendar, Nicola Buzzatti, Giovanni La Canna, Ottavio Alfieri, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Severe mitral regurgitation (MR) confers a poor prognosis, in particular for patients with heart failure. Based on the results of the Euro Heart Survey, a large proportion of patients with mitral regurgitation is not referred to surgery and many other patients are rejected for cardiac surgery due to the high surgical risk or co-pathologies. Improving ventricular function with ACE inhibitors, beta-blockers and CRT may reduce mitral regurgitation, but for most patients a mechanical intervention is ultimately preferable. Mitral valve surgery is invasive and requires a long recovery period; therefore, less invasive and effective approaches are highly desirable, particularly in high risk patients. Therefore, new techniques have been recently developed to treat MR with percutaneous approach. The MitraClip device (Abbott Vascular, Menlo Park, CA) is used to treat both functional and degenerative mitral valve regurgitation. Its safety and efficacy has been initially tested in the Endovascular Valve Edge-to-Edge REpair Study (EVEREST), while MitraClip has been compared to surgery in the EVEREST II randomized trial. Besides EVEREST trials, safety and efficacy of the device as well as its health economic value is under evaluation in ongoing registries. Although the field of catheter based management of MR is at an early stage, initial clinical results have demonstrated that catheter based approaches can reduce MR, suggesting there is a great deal of potential for clinical benefit to patients with MR.

Original languageEnglish
Pages (from-to)1155-1164
Number of pages10
JournalInternational Journal of Cardiovascular Imaging
Volume27
Issue number8
DOIs
Publication statusPublished - 2011

Fingerprint

Mitral Valve Insufficiency
Mitral Valve
Catheters
Clinical Trials
Protective Devices
Ventricular Function
Angiotensin-Converting Enzyme Inhibitors
Thoracic Surgery
Blood Vessels
Registries
Heart Failure
Economics
Pathology
Safety
Equipment and Supplies
Health

Keywords

  • Mitral valve repair
  • Trans-catheter mitral valve

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Clinical trial experience with the MitraClip catheter based mitral valve repair system. / Maisano, Francesco; Godino, Cosmo; Giacomini, Andrea; Denti, Paolo; Arendar, Iryna; Buzzatti, Nicola; La Canna, Giovanni; Alfieri, Ottavio; Colombo, Antonio.

In: International Journal of Cardiovascular Imaging, Vol. 27, No. 8, 2011, p. 1155-1164.

Research output: Contribution to journalArticle

Maisano, Francesco ; Godino, Cosmo ; Giacomini, Andrea ; Denti, Paolo ; Arendar, Iryna ; Buzzatti, Nicola ; La Canna, Giovanni ; Alfieri, Ottavio ; Colombo, Antonio. / Clinical trial experience with the MitraClip catheter based mitral valve repair system. In: International Journal of Cardiovascular Imaging. 2011 ; Vol. 27, No. 8. pp. 1155-1164.
@article{da92861b96144fca8bdf1c8548a2bdd9,
title = "Clinical trial experience with the MitraClip catheter based mitral valve repair system",
abstract = "Severe mitral regurgitation (MR) confers a poor prognosis, in particular for patients with heart failure. Based on the results of the Euro Heart Survey, a large proportion of patients with mitral regurgitation is not referred to surgery and many other patients are rejected for cardiac surgery due to the high surgical risk or co-pathologies. Improving ventricular function with ACE inhibitors, beta-blockers and CRT may reduce mitral regurgitation, but for most patients a mechanical intervention is ultimately preferable. Mitral valve surgery is invasive and requires a long recovery period; therefore, less invasive and effective approaches are highly desirable, particularly in high risk patients. Therefore, new techniques have been recently developed to treat MR with percutaneous approach. The MitraClip device (Abbott Vascular, Menlo Park, CA) is used to treat both functional and degenerative mitral valve regurgitation. Its safety and efficacy has been initially tested in the Endovascular Valve Edge-to-Edge REpair Study (EVEREST), while MitraClip has been compared to surgery in the EVEREST II randomized trial. Besides EVEREST trials, safety and efficacy of the device as well as its health economic value is under evaluation in ongoing registries. Although the field of catheter based management of MR is at an early stage, initial clinical results have demonstrated that catheter based approaches can reduce MR, suggesting there is a great deal of potential for clinical benefit to patients with MR.",
keywords = "Mitral valve repair, Trans-catheter mitral valve",
author = "Francesco Maisano and Cosmo Godino and Andrea Giacomini and Paolo Denti and Iryna Arendar and Nicola Buzzatti and {La Canna}, Giovanni and Ottavio Alfieri and Antonio Colombo",
year = "2011",
doi = "10.1007/s10554-011-9872-8",
language = "English",
volume = "27",
pages = "1155--1164",
journal = "International Journal of Cardiovascular Imaging",
issn = "1569-5794",
publisher = "Springer Netherlands",
number = "8",

}

TY - JOUR

T1 - Clinical trial experience with the MitraClip catheter based mitral valve repair system

AU - Maisano, Francesco

AU - Godino, Cosmo

AU - Giacomini, Andrea

AU - Denti, Paolo

AU - Arendar, Iryna

AU - Buzzatti, Nicola

AU - La Canna, Giovanni

AU - Alfieri, Ottavio

AU - Colombo, Antonio

PY - 2011

Y1 - 2011

N2 - Severe mitral regurgitation (MR) confers a poor prognosis, in particular for patients with heart failure. Based on the results of the Euro Heart Survey, a large proportion of patients with mitral regurgitation is not referred to surgery and many other patients are rejected for cardiac surgery due to the high surgical risk or co-pathologies. Improving ventricular function with ACE inhibitors, beta-blockers and CRT may reduce mitral regurgitation, but for most patients a mechanical intervention is ultimately preferable. Mitral valve surgery is invasive and requires a long recovery period; therefore, less invasive and effective approaches are highly desirable, particularly in high risk patients. Therefore, new techniques have been recently developed to treat MR with percutaneous approach. The MitraClip device (Abbott Vascular, Menlo Park, CA) is used to treat both functional and degenerative mitral valve regurgitation. Its safety and efficacy has been initially tested in the Endovascular Valve Edge-to-Edge REpair Study (EVEREST), while MitraClip has been compared to surgery in the EVEREST II randomized trial. Besides EVEREST trials, safety and efficacy of the device as well as its health economic value is under evaluation in ongoing registries. Although the field of catheter based management of MR is at an early stage, initial clinical results have demonstrated that catheter based approaches can reduce MR, suggesting there is a great deal of potential for clinical benefit to patients with MR.

AB - Severe mitral regurgitation (MR) confers a poor prognosis, in particular for patients with heart failure. Based on the results of the Euro Heart Survey, a large proportion of patients with mitral regurgitation is not referred to surgery and many other patients are rejected for cardiac surgery due to the high surgical risk or co-pathologies. Improving ventricular function with ACE inhibitors, beta-blockers and CRT may reduce mitral regurgitation, but for most patients a mechanical intervention is ultimately preferable. Mitral valve surgery is invasive and requires a long recovery period; therefore, less invasive and effective approaches are highly desirable, particularly in high risk patients. Therefore, new techniques have been recently developed to treat MR with percutaneous approach. The MitraClip device (Abbott Vascular, Menlo Park, CA) is used to treat both functional and degenerative mitral valve regurgitation. Its safety and efficacy has been initially tested in the Endovascular Valve Edge-to-Edge REpair Study (EVEREST), while MitraClip has been compared to surgery in the EVEREST II randomized trial. Besides EVEREST trials, safety and efficacy of the device as well as its health economic value is under evaluation in ongoing registries. Although the field of catheter based management of MR is at an early stage, initial clinical results have demonstrated that catheter based approaches can reduce MR, suggesting there is a great deal of potential for clinical benefit to patients with MR.

KW - Mitral valve repair

KW - Trans-catheter mitral valve

UR - http://www.scopus.com/inward/record.url?scp=84942303263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942303263&partnerID=8YFLogxK

U2 - 10.1007/s10554-011-9872-8

DO - 10.1007/s10554-011-9872-8

M3 - Article

AN - SCOPUS:84942303263

VL - 27

SP - 1155

EP - 1164

JO - International Journal of Cardiovascular Imaging

JF - International Journal of Cardiovascular Imaging

SN - 1569-5794

IS - 8

ER -